{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:25:50Z","timestamp":1769081150107,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":645,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Servier, China"},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>A therapeutic strategy for chronic heart failure (HF) is to lower resting heart rate (HR). Ivabradine is a well-known HR-lowering agent, but limited prospective data exist regarding its use in Chinese patients. This study aimed to evaluate the effectiveness and safety of ivabradine in Chinese patients with chronic HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This multicentre, single-arm, prospective, observational study enrolled Chinese patients with chronic HF. The primary outcome was change from baseline in HR at 1 and 6 months, measured by pulse counting. Effectiveness was also evaluated using laboratory tests, the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (CSS) and overall summary score (OSS), and New York Heart Association (NYHA) class. Treatment-emergent adverse events (TEAEs) were assessed. A post hoc analysis examined the effectiveness and safety of ivabradine combined with an angiotensin receptor\u2013neprilysin inhibitor (ARNI) or beta-blocker. A total of 1003 patients were enrolled [mean age 54.4 \u00b1 15.0 years, 773 male (77.1%), mean baseline HR 88.5 \u00b1 11.3 b.p.m., mean blood pressure 115.7\/74.4 \u00b1 17.2\/12.3 mmHg, mean left ventricular ejection fraction 30.9 \u00b1 7.6%, NYHA Classes III and IV in 48.8% and 22.0% of patients, respectively]. HR decreased by a mean of 12.9 and 16.1 b.p.m. after 1 and 6 months, respectively (both P &amp;lt; 0.001). At Month 6, improvements in the KCCQ CSS and OSS of \u22655 points were observed in 72.1% and 74.1% of patients, respectively (both P &amp;lt; 0.001). Left ventricular ejection fraction increased by 12.1 \u00b1 11.6 (P &amp;lt; 0.001), and 66.7% of patients showed improvement in NYHA class (P &amp;lt; 0.001). At Month 6, the overall proportion of patients in NYHA Classes III and IV was reduced to 13.5% and 2.1%, respectively. Serum brain natriuretic peptide (BNP) and N-terminal pro-BNP changed by \u2212331.9 ng\/L (\u22121238.6, \u2212134.0) and \u22121113.8 ng\/L (\u22122202.0, \u2212297.2), respectively (P &amp;lt; 0.001). HR reductions and improvements in NYHA and KCCQ scores with ivabradine were similar with and without use of ARNIs or beta-blockers. Of 498 TEAEs in 296 patients (29.5%), 73 TEAEs in 55 patients (5.5%) were considered related to ivabradine [most frequent sinus bradycardia (n = 7) and photopsia (n = 7)]. TEAEs were reported in a similar number of patients in ARNI and beta-blocker subgroups (21.9\u201335.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ivabradine treatment reduced HR and improved cardiac function and health-related quality of life in Chinese patients with chronic HF. Benefits were seen irrespective of whether or not patients were also taking ARNIs or beta-blockers. Treatment was well tolerated with a similar profile to previous ivabradine studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14581","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T06:54:39Z","timestamp":1704783279000},"page":"846-858","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and Safety of Ivabradine in Chinese Patients with Chronic Heart Failure: An Observational Study"],"prefix":"10.1093","volume":"11","author":[{"given":"Jingmin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaofen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Hunan Provincial People's Hospital , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiefu","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fuwai Hospital, CAMS PUMC , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baopeng","family":"Tang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University , Urumqi ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyuan","family":"Han","sequence":"additional","affiliation":[{"name":"Shanxi Cardiovascular Hospital , Taiyuan ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University , Chengdu ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Hospital of Hebei Medical University , Shijiazhuang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Ding","sequence":"additional","affiliation":[{"name":"Peking University First Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caizhen","family":"Qian","sequence":"additional","affiliation":[{"name":"Zhuji People's Hospital , Shaoxing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohai","family":"Su","sequence":"additional","affiliation":[{"name":"Jinan Central Hospital Affiliated to Shandong University , Jinan ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuansheng","family":"Shen","sequence":"additional","affiliation":[{"name":"Huizhou Municipal Central Hospital , Huizhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Shi","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Zunyi Medical College , Zunyi ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangqing","family":"Kong","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Ge","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University (Qingdao) , Qingdao ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Guo","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"First People's Hospital of Yunnan Province , Kunming ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuemin","family":"Sun","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital , Tianjin ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Zhejiang ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Servier (Tianjin) Pharmaceutical Co., Ltd , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-7332","authenticated-orcid":false,"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the POSITIVE investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"2026012113161143100_ehf214581-bib-0001","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.ijcard.2012.06.116","article-title":"Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study","volume":"167","author":"Kalra","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0002","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/1074248420931617","article-title":"Long-term adherence to renin\u2013angiotensin system inhibitors and \u03b2-blockers after heart failure hospitalization in senior patients","volume":"25","author":"Qin","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012113161143100_ehf214581-bib-0003","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/14779072.2018.1489235","article-title":"Role of ivabradine and heart rate lowering in chronic heart failure: Guideline update","volume":"16","author":"Chow","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026012113161143100_ehf214581-bib-0004","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026012113161143100_ehf214581-bib-0005","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3760\/cma.j.issn.0253-3758.2017.03.005","article-title":"Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: Subgroup analysis of Chinese patients in the SHIFT study [in Chinese]","volume":"45","author":"Hu","year":"2017","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"2026012113161143100_ehf214581-bib-0006","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40256-021-00500-x","article-title":"Real-world effectiveness of ivabradine in Chinese patients with chronic heart failure: Interim analysis of the POSITIVE study","volume":"22","author":"Jingmin","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026012113161143100_ehf214581-bib-0007","first-page":"253","volume-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"Dolgin","year":"1994","edition":"9th ed"},{"key":"2026012113161143100_ehf214581-bib-0008","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0009","volume-title":"Colentor\u00ae (ivabradine hydrochloride) tablets package insert 2017","author":"Servier (Tianjin) Pharmaceutical Co., Ltd"},{"key":"2026012113161143100_ehf214581-bib-0010","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0011","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"2026012113161143100_ehf214581-bib-0012","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and safety of ivabradine in Japanese patients with chronic heart failure\u2014J-SHIFT study","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2026012113161143100_ehf214581-bib-0013","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","article-title":"Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study","volume":"217","author":"Hidalgo","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0014","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study","volume":"102","author":"B\u00f6hm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0015","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004112","article-title":"Ivabradine in heart failure: The representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a broad population of patients with chronic heart failure","volume":"10","author":"Das","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012113161143100_ehf214581-bib-0016","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050067","article-title":"Observational research, randomised trials, and two views of medical science","volume":"5","author":"Vandenbroucke","year":"2008","journal-title":"PLoS Med"},{"key":"2026012113161143100_ehf214581-bib-0017","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.tcm.2021.10.011","article-title":"Clinical application of results of the ISCHEMIA trial","volume":"33","author":"Kanoun Schnur","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"2026012113161143100_ehf214581-bib-0018","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012113161143100_ehf214581-bib-0019","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113161143100_ehf214581-bib-0020","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijcard.2017.08.001","article-title":"Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study","volume":"249","author":"Zachariah","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0021","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012113161143100_ehf214581-bib-0022","doi-asserted-by":"publisher","first-page":"40","DOI":"10.14740\/cr958","article-title":"Effect of ivabradine on left ventricular diastolic function, exercise tolerance and quality of life in patients with heart failure: A systemic review and meta-analysis of randomized controlled trials","volume":"11","author":"Koroma","year":"2020","journal-title":"Cardiol Res"},{"key":"2026012113161143100_ehf214581-bib-0023","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: A systematic review and meta-analysis","volume":"23","author":"Turgeon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113161143100_ehf214581-bib-0024","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"2026012113161143100_ehf214581-bib-0025","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"2026012113161143100_ehf214581-bib-0026","doi-asserted-by":"publisher","first-page":"55L","DOI":"10.1016\/S0002-9149(97)00849-7","article-title":"Effects of beta blockers on symptoms and functional capacity in heart failure","volume":"80","author":"Fowler","year":"1997","journal-title":"Am J Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0027","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012113161143100_ehf214581-bib-0028","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19169801","article-title":"Approaches to peripheral artery disease in diabetes: Are there any differences?","volume":"19","author":"Achim","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026012113161143100_ehf214581-bib-0029","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012113161143100_ehf214581-bib-0030","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012884","article-title":"Characteristics, management, and outcomes of patients hospitalized for heart failure in China: The China PEACE retrospective heart failure study","volume":"8","author":"Yu","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026012113161143100_ehf214581-bib-0031","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.665202","article-title":"In-hospital heart rate reduction with beta blockers and ivabradine early after recovery in patients with acute decompensated heart failure reduces short-term mortality and rehospitalization","volume":"8","author":"Faragli","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012113161143100_ehf214581-bib-0032","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2017.12.093","article-title":"Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program","volume":"260","author":"Lopatin","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012113161143100_ehf214581-bib-0033","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/ehf2.13182","article-title":"Combination of ivabradine and sacubitril\/valsartan in patients with heart failure and reduced ejection fraction","volume":"8","author":"Lee","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113161143100_ehf214581-bib-0034","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/846\/64540091\/eschf_11_2_846.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/846\/64540091\/eschf_11_2_846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:18:09Z","timestamp":1769019489000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/2\/846\/8271371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,9]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14581","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"2022-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}